Article History
Received: 14 December 2017
Accepted: 23 July 2018
First Online: 29 August 2018
Ethics approval and consent to participate
: According to Therapeutic Goods (Excluded Goods) Order No. 1 of 2011 (the Order), autologous human cells and tissues that are used: for use in the patient from which they were taken; used under the supervision of a medical practitioner who is caring for that patient and for a single indication in a single course of treatment. They have been declared not to be therapeutic goods for the purpose of the Therapeutic Goods Act 1989 (the Act) by the Secretary of the Department of Health (the Secretary), therefore, they are not regulated by the TGA[1]. [1] A copy of the Order can be found at This regulation was valid until 31st May 2019 before the new regulation comes into effect. Hence, an ethics approval was not required for this study. This patient has consented to participate in the treatment of OA with autologous adipose-derived SVF. The patient has provided informed consent for this case report to be published. The written consent was signed on the date of initial treatment and again at the 3-year follow-up interval. It was not signed separately to the routine medical manuscript submissions. Patient privacy and confidentiality has been taken into consideration and the patient wishes for her personal details to remain private.
: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.